Ikarian Capital’s NextCure NXTC Stock Holding History

Ikarian Capital’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$461K	Buy	288,303 +50,000	+21%	+$370K	0.05%	122
2026 Q1	$2.51M	Hold	238,303	–	–	0.2%	86
2025 Q4	$3.38M	Buy	+238,303	New	+$2.47M	0.26%	77
2022 Q3	–	Sell	-5,953	Closed	-$336K	–	147
2022 Q2	$336K	Sell	5,953 -5,802	-49%	-$303K	0.06%	108
2022 Q1	$686K	Buy	11,755 +584	+5%	+$36.5K	0.09%	114
2021 Q4	$804K	Sell	11,171 -31,259	-74%	-$2.62M	0.12%	107
2021 Q3	$3.43M	Sell	42,430 -643	-1%	-$56.4K	0.24%	92
2021 Q2	$4.15M	Buy	43,073 +5,244	+14%	+$537K	0.34%	77
2021 Q1	$4.54M	Buy	37,829 +21,162	+127%	+$3.06M	0.15%	128
2020 Q4	$2.18M	Hold	16,667	–	–	0.1%	152
2020 Q3	$1.76M	Buy	+16,667	New	+$2.05M	0.13%	115

Other funds holding NXTC

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Verdad Advisers Boston, Massachusetts $104M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Ikarian Capital's NXTC Position: Q2 2026 in Review

Ikarian Capital increased its NextCure (NXTC) stake by 21% in Q2 2026, buying an estimated $370K and bringing the position to 288,303 shares worth $461K. The position accounts for 0.05% of the portfolio, ranked #122.

Ikarian Capital first reported a position in NXTC in Q3 2020 and has held it in 11 quarters since. The position peaked at $4.54M in Q1 2021. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

Ikarian Capital held 288,303 shares of NextCure worth $461K as of Q2 2026.
Ikarian Capital bought 50,000 NextCure shares in Q2 2026, an estimated $370K.
NextCure made up 0.05% of Ikarian Capital's portfolio in Q2 2026, its #122 holding.
Ikarian Capital first reported a position in NextCure in Q3 2020 and has held it in 11 quarters since.
Ikarian Capital's NextCure position peaked at $4.54M in Q1 2021.
30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.